InflaRx (IFRX) Registration filing summary

Company overview and business model

• Pioneers anti-inflammatory therapeutics using proprietary anti-C5a and anti-C5aR technologies targeting complement-mediated diseases.

• Lead program izicopan is an oral C5aR inhibitor in clinical development for ANCA-associated vasculitis (AAV) and other renal diseases.

• Vilobelimab, an intravenous anti-C5a monoclonal antibody, has shown clinical activity in multiple inflammatory indications and received emergency use authorization for COVID-19.

• IFX002, a next-generation anti-C5a antibody, is in preclinical development for chronic inflammatory diseases.

• Strategy includes advancing clinical programs, seeking partnerships, and expanding indications for lead assets.

Financial performance and metrics

• As of June 30, 2026, market value of outstanding ordinary shares held by non-affiliates was approximately $269 million, based on 120,111,823 shares at $2.24 per share.

• Ordinary shares are listed on Nasdaq under the symbol "IFRX"; last sale price on August 5, 2026, was $1.77 per share.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes and other business opportunities.

• Additional details on use of proceeds will be provided in prospectus supplements for specific offerings.